Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
Would you use anabolic agents (romosozumab or PTH analogues) for osteoporosis treatment in patients with CKD?
Related Questions
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
Would you consider PTH-analog therapy in a woman with osteoporotic vertebral fractures who has asymptomatic non-obstructive renal stones and normal 24-hour urine calcium level?
Do you recommend osteoporosis medication in postmenopausal females on anastrozole with very low Vitamin D (4.5)?
How do you approach management of patients who are wheelchair bound with a history of osteopenia or osteoporosis?
Would you use PTH analog in a patient with severe osteoporosis (T score below - 3.5) who has been found to have idiopathic hypercalciuria with normal labs (PTH, vit D, Ca)?
Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?
During treatment of severe osteoporosis, with PTH analogs (abaloparatide or) would rise in alkaline phosphatase level > 200 (in setting of normal GGT) warrant discontinuation of medication?
Would you use romosozumab in a patient with a cardiovascular event more than 2 years prior?
Is there any evidence regarding bone density gains/fracture reduction in the setting of treatment with romosozumab after a two year course of teriparatide?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
